TransMedics Group, Inc.

TMDX Healthcare Medical Devices

TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.

Revenue
+41.2%
EPS
−31.0%
Free cash flow
−55.4%
Total debt
−89.3%

Quarter to September 2026, against a year earlier

87.82 18.84 +27.31%
Market cap
$2.4B
P/E
16.4×
Fwd P/E
49.4×
Dividend yield
—
F-score
7/9
Altman Z
5.32
Beneish M
−1.32
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26 From the 10-Q filed 5 Nov
Piotroski F-Score

+8 more TTM periods

7 4 3 4
ROE
54.24% 45.22% 36.28% 31.89%
ROA
20.33% 15.13% 12.88% 11.73%
ROIC
13.65% 6.64% 5.62% 48.00%
Return on Tangible Assets
21.72% 19.34% 16.52% 15.77%
Average Days of Receivables
50.81 52.08 56.86 57.65
Free Cash Flow per Share
3.93 4.40 2.29 1.29
Free Cash Flow
133.59 151.36 79.04 44.70
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026